Literature DB >> 24225993

A new mutation in the C-SH2 domain of PTPN11 causes Noonan syndrome with multiple giant cell lesions.

Raphael Carapito1, Nicodème Paul1, Meiggie Untrau1, Louise Ott1, Nadège Corradini2, Sylvaine Poignant3, Loïc Geffroy4, Emmanuelle Caldagues3, Marie-Françoise Heymann5, Elisabeth Cassagnau6, Bertrand Isidor7, Seiamak Bahram1.   

Abstract

Noonan syndrome (NS), an autosomal dominant multisystem disorder, is caused by the dysregulation of the RAS-MAPK pathway and is characterized by short stature, heart defects, pectus excavatum, webbed neck, learning problems, cryptorchidism and facial dysmorphism. We here present the clinical and molecular characterization of a family with NS and multiple giant cell lesions (MGCLs). The proband is a 12-year-old girl with NS and MGCL. Her mother shows typical NS without MGCL. Whole-exome sequencing of the girl, her mother and her healthy maternal grand parents revealed a previously unobserved mutation in exon 5 of the PTPN11 gene (c.598 A>T; p.N200Y), transmitted from the mother to the proband. As no other modification in the RAS-MAPK pathway genes as related to Rasopathies was detected in the proband, this report demonstrates for the first time that a unique mutation affecting this, otherwise unaffected signaling route, can cause both NS and NS/MGCL in the same family. This observation further confirms that NS/MGCL is not a distinct entity but rather that MGCL represents a rare complication of NS. Moreover, the localization of the p.N200Y mutation suggests an alternative molecular mechanism for the excessive phosphatase activity of the PTPN11-encoded protein.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24225993     DOI: 10.1038/jhg.2013.118

Source DB:  PubMed          Journal:  J Hum Genet        ISSN: 1434-5161            Impact factor:   3.172


  16 in total

Review 1.  Shp-2 tyrosine phosphatase: signaling one cell or many.

Authors:  G S Feng
Journal:  Exp Cell Res       Date:  1999-11-25       Impact factor: 3.905

Review 2.  The 'Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling.

Authors:  Benjamin G Neel; Haihua Gu; Lily Pao
Journal:  Trends Biochem Sci       Date:  2003-06       Impact factor: 13.807

3.  Complete response to imatinib in relapsing pigmented villonodular synovitis/tenosynovial giant cell tumor (PVNS/TGCT).

Authors:  J-Y Blay; H El Sayadi; P Thiesse; J Garret; I Ray-Coquard
Journal:  Ann Oncol       Date:  2008-02-21       Impact factor: 32.976

4.  SOS1 and PTPN11 mutations in five cases of Noonan syndrome with multiple giant cell lesions.

Authors:  Claire Beneteau; Hélène Cavé; Anne Moncla; Nathalie Dorison; Arnold Munnich; Alain Verloes; Bruno Leheup
Journal:  Eur J Hum Genet       Date:  2009-04-08       Impact factor: 4.246

Review 5.  SHP-2, SH2-containing protein tyrosine phosphatase-2.

Authors:  M Stein-Gerlach; C Wallasch; A Ullrich
Journal:  Int J Biochem Cell Biol       Date:  1998-05       Impact factor: 5.085

6.  PTPN11 mutations in Noonan syndrome: molecular spectrum, genotype-phenotype correlation, and phenotypic heterogeneity.

Authors:  Marco Tartaglia; Kamini Kalidas; Adam Shaw; Xiaoling Song; Dan L Musat; Ineke van der Burgt; Han G Brunner; Débora R Bertola; Andrew Crosby; Andra Ion; Raju S Kucherlapati; Steve Jeffery; Michael A Patton; Bruce D Gelb
Journal:  Am J Hum Genet       Date:  2002-05-01       Impact factor: 11.025

Review 7.  Disorders of dysregulated signal traffic through the RAS-MAPK pathway: phenotypic spectrum and molecular mechanisms.

Authors:  Marco Tartaglia; Bruce D Gelb
Journal:  Ann N Y Acad Sci       Date:  2010-10-19       Impact factor: 5.691

8.  Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome.

Authors:  M Tartaglia; E L Mehler; R Goldberg; G Zampino; H G Brunner; H Kremer; I van der Burgt; A H Crosby; A Ion; S Jeffery; K Kalidas; M A Patton; R S Kucherlapati; B D Gelb
Journal:  Nat Genet       Date:  2001-12       Impact factor: 38.330

Review 9.  The RASopathies: developmental syndromes of Ras/MAPK pathway dysregulation.

Authors:  William E Tidyman; Katherine A Rauen
Journal:  Curr Opin Genet Dev       Date:  2009-05-19       Impact factor: 5.578

Review 10.  Noonan syndrome.

Authors:  Amy E Roberts; Judith E Allanson; Marco Tartaglia; Bruce D Gelb
Journal:  Lancet       Date:  2013-01-10       Impact factor: 79.321

View more
  3 in total

Review 1.  Giant Cell Lesions of the Jaws Involving RASopathy Syndromes.

Authors:  Melissa Luna; Nicholas Wolsefer; Carlos-Xavier Zambrano; Ivan James Stojanov
Journal:  Acta Stomatol Croat       Date:  2022-03

2.  miRNA Genetic Variants Alter Their Secondary Structure and Expression in Patients With RASopathies Syndromes.

Authors:  Joseane Biso de Carvalho; Guilherme Loss de Morais; Thays Cristine Dos Santos Vieira; Natana Chaves Rabelo; Juan Clinton Llerena; Sayonara Maria de Carvalho Gonzalez; Ana Tereza Ribeiro de Vasconcelos
Journal:  Front Genet       Date:  2019-11-13       Impact factor: 4.599

3.  Imatinib, a New Adjuvant Medical Treatment for Multifocal Villonodular Synovitis Associated to Noonan Syndrome: A Case Report and Literature Review.

Authors:  Romain Dalla-Torre; Vincent Crenn; Pierre Menu; Bertrand Isidor; Pascale Guillot; Benoit Le Goff; Loic Geffroy; Marc Dauty; Alban Fouasson-Chailloux
Journal:  Front Med (Lausanne)       Date:  2022-01-17
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.